On Monday, Divi Laboratories consolidated net profit, which has been increased by 78 per cent to Rs 895 crore in the fourth quarter on March 31, 2022. In the last quarter, the drugmaker has reported a net profit of Rs 502 crore, and revenue from operation rose to Rs 2 518 crores, against Rs 1 788 crore in the year-ago period, as per the company’s statement.
- Adani Green Energy Shares Soar 7% as Arm Comisiones 57 MW Wind Power Component
- IRFC Shares Rally 3% on Emerging L1 for Banhardih Coal Block Financing
- Minda Corporation Shares Rally 5% on Plans to Acquire Stake in Flash Electronics
- Stocks Under F&O Ban: Hindustan Copper, RBL Bank, and Others
- Stocks in Focus: J&K Bank, IRFC, Adani Green Energy, Vodafone Idea, and Others
For the year ended in March 2022, Divi Laboratories Ltd posted a consolidated net profit of Rs 2,960 crore against Rs 1,984 crore in FY21.
Revenue from operations rose to Rs 8,960 crore compared to Rs 6,969 crore in 2020-21.
The company said its board had recommended a dividend of Rs 30 per share of the face value of Rs 2 (1,500 per cent) for 2021-22, subject to members’ approval at the ensuing annual general meeting.
Shares of the company were trading 6.37 per cent down at Rs 4,032.35 apiece on the Bombay Stock Exchange (BSE).
